metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Manifestations of SARS-COV-2 in patients with chronic liver disease
Información de la revista
Vol. 27. Núm. S3.
Abstracts from XVII Mexican Congress of Hepatology
(diciembre 2022)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 27. Núm. S3.
Abstracts from XVII Mexican Congress of Hepatology
(diciembre 2022)
Open Access
Manifestations of SARS-COV-2 in patients with chronic liver disease
Visitas
210
AE Jiménez-Partida, MA Jiménez-Luévano, MA Jiménez-Partida, A Bravo-Cuellar, Y Cortes-Aguilar
Regional Hospital “Dr. Valentín Gómez Farías” Gastroenterology Service. ISSSTE. Mexico
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Resumen
Texto completo
Descargar PDF
Estadísticas
Suplemento especial
Este artículo forma parte de:
Vol. 27. Núm S3

Abstracts from XVII Mexican Congress of Hepatology

Más datos
Introduction and Objectives

This study aimed to analyze the degree of severity of SARS-CoV-2 infection in patients with the previous chronic liver disease through clinical, laboratory and histological variables.

Materials and Methods

From November 2021 to July 2021, at the Valentín Gómez Farías Hospital, a Gastroenterology service, 70 patients were treated with prior informed consent and endorsed by the ethics committee. For this study, 51 individuals with chronic liver disease and diagnosis of SARS-CoV-2 were included: 25 with steatohepatitis and 26 with liver cirrhosis. The following findings were observed:

Results

Histological findings:

• Micro vesicular steatosis.

• Mild mortal and lobular inflammatory activity.

• High viral load in the vascular endothelium (48 to 53%) and cytopathic effect of the SARS-CoV-2 virus.

• Ischemia due to hypoperfusion mainly due to myocardial injury.

• Immune hyperactivation.

• Drug-reactive liver injury.

• Apoptosis

Discussion

The COVID-19 pandemic is more severe in vulnerable patients, mainly older adults, male gender and comorbidities such as hypertension, diabetes, nephropathy, heart disease, lung disease, immunosuppression and patients with liver disease. Of these, 60% have severe symptoms and a mortality of 34%.

Conclusions

COVID-19 is the leading cause of death in Mexico. High-risk entities in this viremia are of great global prevalence. Steatohepatitis (NASH) and liver cirrhosis predispose high mortality and complications, possibly evidenced by these clinical evaluations and hepatic laboratory tests.

Funding

The resources used in this study were from the hospital without any additional financing

Declaration of interest

The authors declare no potential conflicts of interest.

Texto completo

Table 1. Demographic, biochemical and symptomatology characteristics of the two groups

Previous pathologies  Steatohepatitis  Liver cirrhosis 
Age  55.64  60,84 
Gender  72% women - 28% men  42% women – 58% men 
BMI  30.76  27.84 
Comorbidities     
Overweight/obesity  100%  100% 
DM 2  31%  20% 
Alcoholism  0%  27% 
Autoimmune disease  0%  4% 
Laboratory     
AST  42.24  56.76 
ALT  50.25  69.90 
DHL  308.2  315.6 
Platelets  170  100.38 
Ferritin  496.24  592.5 
D-dimer  530.54  1,064 
Lymphocytes  35.2  29.96 
ESR  32.32  30.06 
PCR  49  47.03 
Oxygen saturation  85.24  85.69 
Clinic:     
Cough  16 (64%)  14 (54%) 
Dyspnea  13 (52%)  12 (46%) 
Pneumonia  5 (20%)  8 (32%) 
Asthenia  6 (24%)  6 (24%) 
Fever  2 (8%)  13 (52%) 
Headache  3 (12%)  8 (31%) 
Anosmia  1 (4%)  1 (4%) 
Shivers  1 (4%)  1 (4%) 
Arthralgia  3 (12%)  2 (8%) 
Diarrhea  1 (4%)  2 (8%) 

Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos